INJ Search


Int Neurourol J > Volume 17(3); 2013 > Article
Lee and Park: Efficacy of Salvage Interferential Electrical Stimulation Therapy in Patients With Medication-Refractory Enuresis: A Pilot Study



In pediatric patients with enuresis, the protocol for salvage therapy in patients in whom first-line therapy was not successful has not yet been established. Interferential electrical stimulation (IF-ES) therapy is advantageous because it is noninvasive and shows high compliance. We aimed to investigate the efficacy and safety of IF-ES therapy on pediatric enuresis in a pilot study.


We investigated 10 patients who underwent IF-ES therapy between August 2012 and March 2013 at our clinic. Patients with a history of previous treatment with desmopressin and anticholinergic agents for at least 3 months and those in whom alarm treatment previously failed or was refused by parents were eligible. Electrical current was given starting at approximately 20 mA and was increased until the patient complained of discomfort. Treatment was performed once a week, 20 minutes per treatment, 6 times per cycle. After each cycle, an interview was performed and voiding diaries were filled. The physician in charge evaluated improvement according to the International Children's Continence Society criteria.


A final analysis was performed in 10 patients (5 male and 5 female patients) in whom therapy for nocturnal enuresis had failed. Eight patients had nonmonosymptomatic enuresis and 2 had monosymptomatic enuresis. The mean age of the patients was 8.5±2.4 years, and the mean number of treatments was 10.6±3.6 times. A full response was observed in 1 patient (10%); a good response, in 1 patient (10%); a partial response, in 7 patients (70%); and no response, in 1 patient (10%).


Our study demonstrated that IF-ES therapy can be a promising treatment for the future, is safe, and can benefit from appropriate clinical trials in carefully selected groups. IF-ES therapy is expected to be a safe and effective treatment modality for children with enuresis.



    Enuresis is defined by the International Children's Continence Society (ICCS) as loss of discrete amounts of urine during sleep in children older than 5 years [1]. Enuresis in children is generally benign but can cause emotional stress to children and their parents [2]. The incidence of enuresis in Korean children has not yet been reported; however, Lee et al. [3] reported that the incidence of enuresis in the Pusan province of Korea was similar to that in European children (12.8%). In Seoul National University Children's Hospital, we often encounter children with enuresis, and some do not show symptom improvement with conventional treatment.
    Nocturnal enuresis (NE) can be classified as monosymptomatic enuresis (MNE) and nonmonosymptomatic enuresis (NMNE) according to the ICCS [4,5]. MNE is defined as enuresis in children without any other lower urinary tract symptoms (LUTS), and NMNE is defined as enuresis in children with LUTS and with a history of bladder dysfunction. The treatment for NE is identical in both MNE and NMNE, although in NMNE, underlying bowel symptoms and LUTS require treatment before treatment of NE. The treatment protocol for NE recommended by the ICCS is initially lifestyle modification, followed by alarm treatment, and pharmacotherapy that includes desmopressin, anticholinergic agents, and tricyclic antidepressants. The response related to desmopressin treatment is assessed within 1 to 2 weeks, and when a response is shown, it is administered for 3 months. Improvement or remission is then determined, and physicians decide whether desmopressin should be given daily or occasionally [4]. In patients who do not respond to such therapies, further evaluation is necessary; however, no specific guidelines have been established.
    As for salvage treatment, the ICCS recommends re-evaluation and repeat pharmacotherapy for MNE; electrical stimulation (ES) is a modality recommended for patients with NMNE. ES has been widely investigated as an alternative treatment method for LUTS in children [6]. Sacral transcutaneous electrical nerve stimulation (TENS), endoanal, anogenital, posterior tibial nerve stimulation, and sacral implants have been performed. Such ES methods affect neuroplasticity and affect modulation of synapses. ES therapy recovers denervation of muscle fibers and neural reconditioning [7]. Parasacral TENS (PTENS) has been proved to be effective in the treatment of NMNE [8]. De Oliveira et al. [9] recently proved the efficacy of PTENS for MNE in a randomized controlled trial. Interferential ES (IF-ES) is a noninvasive modality first reported in 1987 by Emmerson et al. [10] in the treatment of detrusor instability. IF current produces a 4-kHz carrier frequency current with a sinusoidal waveform with four surface electrodes. IF therapy offers an alternative, noninvasive method of treatment [11]. Kajbafzadeh et al. [12-14] reported that IF-ES is effective for children with myelomeningocele with incontinence, neurogenic bowel dysfunction, and detrusor overactivity.
    Based on such data, we aimed to investigate whether IF-ES is effective for pediatric patients with enuresis in whom pharmacotherapy failed.


    We investigated 10 patients who underwent IF-ES at our institution between August 2012 and March 2013. These 10 children (age, 6-12 years) had either MNE or NMNE, and patients with NMNE were those with enuresis and LUTS and a history of bladder dysfunction. The inclusion criteria were as follows: no improvement despite treatment with desmopressin and anticholinergic agents for at least 3 months, no improvement with previous alarm treatment, or refusal of alarm treatment. Medical history and baseline voiding diaries were obtained. Although medication was not effective, it was maintained during IF-ES treatment therapy and was discontinued when enuresis improved.
    The IF-ES was performed at an outpatient basis. A total of four surface rectangular electrodes (2.5 cm×3.5 cm) producing sinusoidal currents were attached after cleaning the skin of each site with alcohol swabs. Two of these electrodes were attached to the lower abdomen below the costal margin, and two were located on the back over the muscles between T9 and L2 as described in previous studies [11,13]. Electrical current was given starting at approximately 20 mA and was increased until the patient complained of discomfort. When the patient experienced discomfort, the Hz of the IF-ES was not decreased, but the electrical current strength (mA) was decreased until a tolerable level was achieved. The IF-ES protocol of the device was set at the 4-pole vector mode central wave (Gymna Duo 200, Apsun Co., Seoul, Korea). Treatment was performed once a week, 20 minutes per treatment, 6 times per cycle. After each cycle, an interview was performed and voiding diaries were filled.
    The physician in charge evaluated improvement according to the ICCS criteria. Treatment outcome, using the ICCS definitions, was defined as nonresponse (0-49% decrease), partial response (50-89% decrease), good response (90% or greater decrease), and full response (100% decrease or less than 1 symptom occurrence monthly). Such improvement was evaluated by the number of episodes of enuresis on voiding diaries.
    A descriptive analysis was performed with the independent t-test method. A Mann-Whitney U-test was performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA). A P<0.05 was considered to be statistically significant. This study was approved by the Institutional Review Board of Seoul National University Hospital.


    The 10 patients who underwent IF-ES were analyzed. Eight patients had NMNE and 2 had MNE. The demographics of these 10 patients were as follows: The mean±standard deviation age of the patients was 8.5±2.4 years. Five patients were male, and 5 were female. The mean number of treatment was 10.6±3.6 times, and the strength of the electrical current was 24.4-40.4 mA (Table 1). Based on the decrease in number of wet nights in the previous 28 days compared with the baseline symptom frequency at the start of the training, we evaluated the response of treatment according to the ICCS criteria. Full response (100% decrease or less than one symptom occurrence monthly) was observed in 1 patient (10%); good response (90% or greater decrease), in 1 patient (10%); partial response (50-89% decrease), in 7 patients (70%); and no response (0-49% decrease), in 1 patient (10%). Before treatment, 7 patients showed daytime urinary incontinence; 2, daytime urinary frequency; and 2, showed encopresis. Five patients continued pharmacotherapy during IF-ES, and 5 (50%) stopped taking medication because symptoms improved. Three patients (30%) showed a decrease in daytime urinary frequency, and 3 patients (30%) showed an increase in daytime maximal bladder capacity. The mean duration of pharmacotherapy was 23.8±7.9 months. Two patients who complained of encopresis prior to treatment reported slight improvement after cessation of treatment, although the degree of improvement was not objectively evaluated.
    A comparison between NMNE and MNE groups was made (Table 2). The pretreatment and posttreatment numbers of daytime voids were higher, and the pretreatment and posttreatment number of NE episodes was lower in the MNE group, although the differences were not statistically significant.
    Both pretreatment and posttreatment parameters were compared (Table 3). The mean daytime maximal bladder capacity (MBC), which was calculated using the voiding diary maximal voided volume, showed an increase after IF-ES, although the increase was not statistically significant (P=0.210). The mean daytime bladder capacity also calculated by using the voiding diaries increased from 126.5±35.1 mL to 163.5±61.4 mL after treatment, and the improvement was statistically significant (P=0.026). The daytime number of voids showed a small decrease after treatment; however, the decrease was not statistically significant (P=0.868). As for the frequency of enuresis per week, the number of episodes decreased from 6.2±3.3 times per week to 2.4±1.5 times per week, and the decrease was statistically significant (P=0.001).
    Factors affecting the treatment outcome were analyzed (Table 4). Age, pretreatment daytime MBC, pretreatment daytime number of voids, pretreatment number of enuresis/week, total number of treatment sessions, and voltage (mA) per treatment showed no statistically significant correlation.
    All the patients received therapy without cessation until it was stopped by the physician. Pain was tolerable in all the patients, and no skin problems or physical discomfort were reported.


    In pediatric patients with enuresis, salvage treatment after failure of first-line therapy has not yet been established. In patients with NMNE, anticholinergic agents, botulinum toxin A, centrally active medications such as imipramine, and prostaglandin synthesis inhibitors and prostaglandin receptor antagonists can be prescribed to decrease bladder overactivity. Advanced urotherapies such as biofeedback and ES are also recommended as salvage modalities [3].
    The mechanism of ES has not yet been proved; however, most studies report that afferent sacral nerve stimulation causes an interneuronal change of the spinal reflex, which induces an inhibitory stimuli in the bladder efferent nerve [15]. However, consensus has not been reached concerning the precise mechanisms, and despite multiple efforts to examine the efficacy of such salvage treatment methods using ES, no gold standard method has been established, which causes frustration to the physician and patients and family members.
    In our study, the primary outcome was safety, the secondary outcome was tolerability, and the tertiary outcome was efficacy. Although Satter [16] reported that irritation or contact dermatitis after IF-ES commonly occurs, neither condition occurred in our case. Proper electrode use and skin contact are also important to prevent electrical burns. Based on these study goals, that no adverse effects were reported was an indication that the results were satisfactory. That no patients discontinued therapy and completed all required sessions seemed to be an indicator of tolerability. That 7 patients (70%) showed improvement in daytime urinary incontinence was a promising finding of our study. Considering that the efficacy of IF-ES on pediatric urinary incontinence has already been reported [14], such treatment benefits are attractive merits for patient and parents. An increase in daytime MBC in 3 patients (30%) was also a promising finding.
    In addition, the improvement of encopresis in 20% of the patients is an additional benefit in patients with neurogenic bowel symptoms. Queralto et al. [17] reported that interferential therapy is effective in the treatment of slow transit constipation and has less complications and is less expensive than sacral neuromodulation. Chase et al. [11] reported that when performing IF-ES in patients with urinary incontinence, an increase in bowel motility and fluid balance change occurred, suggesting the therapeutic value of both bowel and urinary symptoms after IF-ES.
    This study has a strong advantage of being the first pilot study on the safety, tolerability, and efficacy of IF-ES in Korean pediatric patients with enuresis. Based on the results, IF-ES may be an applicable salvage modality, although the efficacy should be investigated in detail, especially in comparison with conventional methods such as TENS. For neurologically normal patients who do not response to pharmacotherapy for behavior therapy, TENS has been reported to be effective [18], and we expect that IF-ES will also be effective but with fewer adverse effects.
    Despite such positive results, this study has some limitations. First, it was a short-term study, and second, because it was a pilot study, the sample size was relatively small. Due to the limited number of patients, a more detailed analysis of correlation among parameters was not possible, and a comparison between NMNE and MNE groups also had limitations. In addition, in patients with NMNE, underlying bowel symptoms and LUTS were not treated or evaluated with objective parameters, which should be supplemented in future studies. Another limitation was that considering the correlation with risk of skin burns, body mass index evaluation might prove to be valuable in future studies [19,20]. Another potential limitation, which is not unique to our study, is the possibility of spontaneous resolution of symptoms, which should require randomized prospective studies to eliminate possible confounding variables [21]. Another limitation is that due to the continuation of medication in some patients, there was a possibility that pharmacotherapy might have affected the outcome of IF-ES. However, an objective analysis was not possible in our study.
    Although several studies have reported the safety and efficacy of IF-ES for LUTS [6,12,14,22] and enuresis [8,9] in children, IF-ES is not yet practiced in Korea. The reasons appear to be the limited knowledge of the modality, insufficient trained manpower for this outpatient procedure, and cost problems. Another potential limitation of ES is that long-term follow-up data are not available, and Hoebeke et al. [23] reported a high failure rate of 44% 1 year after cessation of ES. Kang et al. [24] reported that because the neural development of children is immature, IF-ES treatment could achieve neuromodulation that could lead to improvement of LUTS. Considering these results, long-term studies are necessary in the future.
    Based on the results of this pilot study, we are planning a prospective study with a larger number of patients and longer follow-up to investigate the efficacy and safety of IF-ES in patients with NE. Based on our research, we may provide valuable information about IF-ES, which may help establish guidelines for salvage therapy and aid clinical practice in the future.


    We are obliged to Mrs. Yeong Ju Ma and Ms. Jinjoo Kim for their valuable help in data acquisition.


    No potential conflict of interest relevant to this article was reported.


    1. Elmissiry M, Abdelkarim A, Badawy H, Elsalmy S, Ali GA. Refractory enuresis in children and adolescents: how can urodynamics affect management and what is the optimum test? J Pediatr Urol 2013;9:348-352. PMID: 22682547.
    crossref pmid
    2. Moffatt ME. Nocturnal enuresis: psychologic implications of treatment and nontreatment. J Pediatr 1989;114(4 Pt 2):697-704. PMID: 2647952.
    crossref pmid
    3. Lee SD, Sohn DW, Lee JZ, Park NC, Chung MK. An epidemiological study of enuresis in Korean children. BJU Int 2000;85:869-873. PMID: 10792168.
    crossref pmid
    4. Neveus T, Eggert P, Evans J, Macedo A, Rittig S, Tekgul S, et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children's Continence Society. J Urol 2010;183:441-447. PMID: 20006865.
    crossref pmid
    5. Franco I, von Gontard A, De Gennaro M. International Childrens's Continence Society. Evaluation and treatment of nonmonosymptomatic nocturnal enuresis: a standardization document from the International Children's Continence Society. J Pediatr Urol 2013;9:234-243. PMID: 23260268.
    crossref pmid
    6. Barroso U Jr, Tourinho R, Lordelo P, Hoebeke P, Chase J. Electrical stimulation for lower urinary tract dysfunction in children: a systematic review of the literature. Neurourol Urodyn 2011;30:1429-1436. PMID: 21717502.
    crossref pmid
    7. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005;174:2268-2272. PMID: 16280802.
    crossref pmid
    8. Lordêlo P, Benevides I, Kerner EG, Teles A, Lordelo M, Barroso U Jr. Treatment of non-monosymptomatic nocturnal enuresis by transcutaneous parasacral electrical nerve stimulation. J Pediatr Urol 2010;6:486-489. PMID: 20837326.
    crossref pmid
    9. de Oliveira LF, de Oliveira DM, da Silva de Paula LI, de Figueiredo AA, de Bessa J Jr, de Sa CA, et al. Transcutaneous parasacral electrical neural stimulation in children with primary monosymptomatic enuresis: a prospective randomized clinical trial. J Urol 2013;190:1359-1363. PMID: 23545102.
    crossref pmid
    10. Emmerson C. A preliminary study of the effect of interferential therapy on detrusor instability in patients with multiple sclerosis. Aust J Physiother 1987;33:64-65.

    11. Chase J, Robertson VJ, Southwell B, Hutson J, Gibb S. Pilot study using transcutaneous electrical stimulation (interferential current) to treat chronic treatment-resistant constipation and soiling in children. J Gastroenterol Hepatol 2005;20:1054-1061. PMID: 15955214.
    crossref pmid
    12. Kajbafzadeh AM, Sharifi-Rad L, Baradaran N, Nejat F. Effect of pelvic floor interferential electrostimulation on urodynamic parameters and incontinency of children with myelomeningocele and detrusor overactivity. Urology 2009;74:324-329. PMID: 19476983.
    crossref pmid
    13. Kajbafzadeh AM, Sharifi-Rad L, Nejat F, Kajbafzadeh M, Talaei HR. Transcutaneous interferential electrical stimulation for management of neurogenic bowel dysfunction in children with myelomeningocele. Int J Colorectal Dis 2012;27:453-458. PMID: 22065105.
    crossref pmid
    14. Kajbafzadeh AM, Sharifi-Rad L, Dianat S. Efficacy of transcutaneous functional electrical stimulation on urinary incontinence in myelomeningocele: results of a pilot study. Int Braz J Urol 2010;36:614-620. PMID: 21044379.
    crossref pmid
    15. Lindström S, Fall M, Carlsson CA, Erlandson BE. The neurophysiological basis of bladder inhibition in response to intravaginal electrical stimulation. J Urol 1983;129:405-410. PMID: 6834523.
    crossref pmid
    16. Satter EK. Third-degree burns incurred as a result of interferential current therapy. Am J Dermatopathol 2008;30:281-283. PMID: 18496434.
    crossref pmid
    17. Queralto M, Vitton V, Bouvier M, Abysique A, Portier G. Interferential therapy: a new treatment for slow transit constipation. a pilot study in adults. Colorectal Dis 2013;15:e35-e39. PMID: 23046450.
    crossref pmid
    18. Lordelo P, Teles A, Veiga ML, Correia LC, Barroso U Jr. Transcutaneous electrical nerve stimulation in children with overactive bladder: a randomized clinical trial. J Urol 2010;184:683-689. PMID: 20561643.
    crossref pmid
    19. Ford KS, Shrader MW, Smith J, McLean TJ, Dahm DL. Full-thickness burn formation after the use of electrical stimulation for rehabilitation of unicompartmental knee arthroplasty. J Arthroplasty 2005;20:950-953. PMID: 16230253.
    crossref pmid
    20. Petrofsky J, Laymon M, Prowse M, Gunda S, Batt J. The transfer of current through skin and muscle during electrical stimulation with sine, square, Russian and interferential waveforms. J Med Eng Technol 2009;33:170-181. PMID: 19205995.
    crossref pmid
    21. Malm-Buatsi E, Nepple KG, Boyt MA, Austin JC, Cooper CS. Efficacy of transcutaneous electrical nerve stimulation in children with overactive bladder refractory to pharmacotherapy. Urology 2007;70:980-983. PMID: 17919697.
    crossref pmid
    22. Oh-Oka H, Fujisawa M. Efficacy on interferential low frequency therapy for elderly overactive bladder patients with urinary incontinence. Nihon Hinyokika Gakkai Zasshi 2007;98:547-551. PMID: 17419364.
    crossref pmid
    23. Hoebeke P, Renson C, Petillon L, Vande Walle J, De Paepe H. Percutaneous electrical nerve stimulation in children with therapy resistant nonneuropathic bladder sphincter dysfunction: a pilot study. J Urol 2002;168:2605-2607. PMID: 12441995.
    crossref pmid
    24. Kang SH, Bae JH, Shim KS, Park HS, Cheon J, Lee JG, et al. Extracorporeal magnetic innervation therapy in children with refractory monosymptomatic nocturnal enuresis. Urology 2007;70:576-580. PMID: 17905120.
    crossref pmid

    Table 1
    Patient demographics and treatment results (n=10)
    Gender/age Daytime symptoms Type of NE Pharmaco- therapy continuation Pharmaco- therapy duration (mo) Pretreatment maximal BC (mL) Post- treatment maximal BC (mL) Pretreatment average BC (mL) Post- treatment average bladder capacity (mL) Pretreatment no. of voids/ day Post- treatment no. of voids/day Pre- treatment no. of enuresis/ wk Post- treatment no. of enuresis/ wk ICCS response Total no. of treatment sessions Average voltage (mA) per IF-ES treatment
    M/6 Incontinence NMNE Continued 16.00 150 150 104.00 110.00 8 11 6 3 PR 8 26.5
    F/6 Incontinence NMNE Continued 33.00 120 100 90.00 110.00 7 5 7 6 NR 6 28.67
    M/7 Incontinence, Encopresis NMNE Discontinued 23.00 180 300 116.60 246.60 8 9 4 2 PR 14 28.86
    F/7 Incontinence NMNE Discontinued 15.00 290 240 148.00 252.50 5 5 7 0.25 FR 17 29.47
    F/8 Incontinence NMNE Discontinued 23.00 180 180 130.00 132.00 5 7 6 3 PR 13 29.23
    M/11 Incontinence NMNE Discontinued 22.00 150 150 161.60 179.60 6 6 6 3 PR 10 24.7
    M/12 Incontinence NMNE Continued 36.00 240 240 100.00 120.00 10 10 5 1 PR 12 29.08
    M/12 Frequency NMNE Discontinued 20.00 110 250 90.00 100.00 13 10 6 1 GR 12 40.42
    F/7 Encopresis MNE Continued 34.00 220 300 200.00 240.00 6 4 7 2 PR 7 24.43
    F/9 Frequency MNE Continued 16.00 220 220 125.00 144.00 5 5 4 1 PR 7 25.14

    NE, nocturnal enuresis; BC, bladder capacity; ICCS, International Children's Continence Society; IF-ES, interferential electricostimulation; NMNE, nonmonosymptomatic nocturnal enuresis; MNE, monosymptomatic nocturnal enuresis; FR, full response; GR, good response; PR, partial response; NR, nonresponse.

    Table 2
    Comparison between nonmonosymptomatic nocturnal enuresis (NMNE) and monosymptomatic nocturnal enuresis (MNE) groups
    Parameter NMNE (n = 8) MNE (n = 2) P-valuea)
    Age (yr) 8.0 ± 1.4 8.75 ± 2.8 0.733
    Medication duration (mo) 25.0 ± 12.7 23.5 ± 7.5 0.825
    Pretreatment average BC (mL) 162.5 ± 53.0 117.5 ± 26.8 0.107
    Post-treatment average BC (mL) 192.0 ± 67.9 156.3 ± 62.5 0.495
    Pretreatment daytime MBC (mL) 220.0 ± 0.0 177.5 ± 60.9 0.373
    Post-treatment daytime MBC (mL) 260.0 ± 56.6 201.3 ± 66.6 0.289
    Pretreatment number of voids/day 5.5 ± 0.7 7.8 ± 2.7 0.297
    Post-treatment number of voids/day 4.5 ± 0.7 7.9 ± 2.4 0.097
    Pretreatment NE episodes/wk 7.5 ± 5.0 5.9 ± 3.2 0.568
    Post-treatment NE episodes/wk 1.5 ± 0.7 2.7 ± 1.6 0.372
    Number of IF-ES sessions 7.0 ± 0.0 11.5 ± 3.5 0.117
    Average voltage (mA) per IF-ES treatment 24.8 ± 0.5 29.6 ± 4.7 0.200

    Values are presented as mean±standard deviation.

    BC, bladder capacity; MBC, maximal bladder capacity; NE, nocturnal enuresis, IF-ET; interferential electrical stimulation.

    a)Analyzed by independent sample t-test.

    Table 3
    Pretreatment and post-treatment effect analysis (n=10)
    Parameter Pretreatment Post-treatment P-valuea)
    Daytime maximal bladder capacity (mL) 183.8 ± 56.6 213.0 ± 66.5 0.210
    Daytime average bladder capacity (mL) 126.5 ± 35.1 163.5 ± 61.4 0.026b)
    Daytime number of voids/day 7.3 ± 2.6 7.2 ± 2.6 0.868
    Number of enuresis episodes/wk 6.2 ± 3.3 2.4 ± 1.5 0.001b)

    Values are presented as mean±standard deviation.

    a)Analyzed by paired t-test. b)P<0.05

    Table 4
    Factors affecting the outcome of interferential electrical stimulation (n=10)
    Parameter P-valuea)
    Age 0.659
    Pretreatment daytime MBC 0.750
    Pretreatment daytime number of voids 0.500
    Pretreatment number of enuresis/wk 0.250
    Total number of treatment sessions 0.500
    Voltage (mA) per treatment 1.000

    MBC, maximal bladder capacity.

    a)Analyzed by Mann Whitney U-test.

    Share :
    Facebook Twitter Linked In Google+
    METRICS Graph View
    • 6 Crossref
    • 7 Scopus
    • 7,963 View
    • 55 Download
    We recommend

    Article Category

    Browse all articles >


    Browse all articles >


    Browse all articles >


    Browse all articles >


    Official Journal of Korean Continence Society & ESSIC (International Society for the Study of BPS) & Korean Society of Urological Research & The Korean Children’s Continence and Enuresis Society & The Korean Association of Urogenital Tract Infection and Inflammation & Korean Society of Geriatric Urological Care
    Editorial Office
    Department of Urology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine,
    29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea
    Tel: +82-2-2001-2237     Fax: +82-2-2001-2247    E-mail:

    Copyright © 2024 by Korean Continence Society.

    Developed in M2PI

    Close layer
    prev next